// App-Quantinova.ai

8508 : Final overall survival for CSLC 0501: Phase 3 study of adjuvant versus neoadjuvant chemotherapy with docetaxel combined carboplatin for resectable stageIB-IIIA non-small cell lung cancer.

Researchers

Presenter

  • Xue-ning Yang

Principal Investigators

  • Wenzhao Zhong

  • Xiao-song Ben

  • Gui-bin Qiao

  • Qun Wang

  • Chang-li Wang

  • Hong-He Luo

  • Zheng Wang

  • Hong-Hong Yan

  • Si-yang Liu

  • Yi-Long Wu

Medical Centers

  • Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH) and Guangdong Academy of Medical Sciences, Guangzhou, China

  • Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China

  • Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH) and Guangdong Academy of Medical Sciences, Guangzhou, China

  • Guangzhou Liuhuaqiao Hospital, Guangzhou, China

  • Huashan Hospital, Fudan University, Shanghai, China

  • Tianjin Medical University Cancer Hospital, Tianjin, China

  • Department of Thoracic Oncology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China

  • Department of General Surgery, Fudan University, Huashan Hospital, Shanghai, China

  • Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH) and Guangdong Academy of Medical Sciences, Guangzhou, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Carboplatin

  • Docetaxel

Outcome

  • Unknown

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT00321334

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved